Intelligence Reports

Free through 31 July

Launch offer — free through 31 July. Request a report on up to 2 trial(s) at no charge, one per company. Every report is human-reviewed before it's sent to you.

Human-reviewed intelligence reports for high-value clinical development decisions. Built from Eichor's public-data intelligence platform, every report is analyst-reviewed and delivered within one business day.

Single-Asset Deep Dive

$1,995

One clinical program, analyzed for:

Execution-risk indicators
Site landscape and grades
Sponsor pressure signals
US (FDAAA 801) and EU (CTIS Article 37) disclosure status
Key public evidence supporting every finding

Portfolio Diligence Pack

$4,995

A consolidated review of 2–4 clinical programs, including:

Portfolio-level risk summary
Site-grade distribution
Sponsor and disclosure posture
Cross-program comparisons
Executive-ready summary

Larger portfolios belong on a platform plan.

Report or subscription? A report is a snapshot for ONE decision — a deal, a rebid, a board meeting — priced per trial, frozen the day it ships. The registry moves daily; a report doesn't. If you need the same questions answered continuously — change alerts, deadline countdowns, refreshed site grades — a monitoring line ($199–999/mo) or a platform plan covers a whole portfolio for less than a few one-off reports a year. Buy the report when the decision is this week; subscribe when the portfolio is ongoing.

Inside a dossier — excerpt (2 of the 8 sections)

Illustrative excerpt showing structure and depth — composed for this page, not taken from a client deliverable. Every delivered report is built fresh from live registry data and human-reviewed.

SECTION 3 — TIMELINE & EXECUTION RISK
Primary completion: 2025-11 (registry) — passed ~8 months ago; status still RECRUITING.
Enrollment: 142 of 210 target (68%) across 24 active sites — trailing plan.
Risk read: the slip is site-concentrated — 3 sites carry 41% of target; two show no
public activity since Q1. Registry maintenance pattern flagged by our models as
consistent with elevated schedule risk (full basis in the delivered dossier).

SECTION 5 — ALTERNATIVE SITE CANDIDATES        (named in the delivered report)
  1. █████████████ Medical Center — ██, TX · 9 same-indication trials · capacity HIGH
  2. ████████ Cancer Institute — ██, FL · 7 same-indication trials · competing load LOW
  3. …up to 10 named candidates, proximity- and experience-matched

The full dossier adds: executive summary · trial profile · full site landscape with grades · sponsor signals (SEC) · US/EU disclosure hygiene · competing-trial context · execution notes.

Built from public registry, FDA, CMS and SEC data with every claim source-linked; sealed in a tamper-evident signed ledger. Covers trial execution and disclosure posture only — not scientific, IP or CMC diligence, and not investment advice.

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →
Launch offer through July 31: first full site unlock free — one per company.